TOP
Nav Bar
  1. General Info
  2. Effects Info
  3. Reference
Drug Interaction Details
01. General Information
Pair Name Luteolin, Osimertinib
Phytochemical Name Luteolin (PubChem CID: 5280445 )
Anticancer drug Name Osimertinib (PubChem CID: 71496458 )
Structure of
Phytochemical		 2D-img
Download
2D MOL 3D MOL
Structure of
Anticancer Drug		 2D-img
Download
2D MOL 3D MOL
02. Combinatorial Therapeutic Effect(s)
Synergistic Effect
Hide/Show
Reversing Drug Resistance
Hide/Show
Combination Pair ID: 839
Ref_1
Pair Name Luteolin, Osimertinib
Disease Info [ICD-11: 2C25.Z] Lung cancer Investigative
Biological Phenomena Inhibition-->Epithelial-mesenchymal transition
Gene Regulation Down-regulation Phosphorylation MET hsa4233
Down-regulation Phosphorylation AKT1 hsa207
Down-regulation Expression HGF hsa3082
In Vitro Model NCI-H1975 Lung adenocarcinoma Homo sapiens (Human) CVCL_1511
Result Luteolin can synergize with osimertinib to overcome MET amplification and overactivation-induced acquired resistance to osimertinib by suppressing the HGF-MET-Akt pathway, suggesting the clinical potential of combining luteolin with osimertinib in NSCLC patients with acquired resistance.
03. Reference
No. Title Href
1 Luteolin overcomes acquired resistance to osimertinib in non-small cell lung cancer cells by targeting the HGF-MET-Akt pathway. Am J Cancer Res. 2023;13(9):4145-4162. Click
It has been 425241 visits since 2024.08
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang
TOP